ATE503461T1 - Pharmazeutische zusammensetzungen zur behandlung von asthma - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von asthma

Info

Publication number
ATE503461T1
ATE503461T1 AT09006110T AT09006110T ATE503461T1 AT E503461 T1 ATE503461 T1 AT E503461T1 AT 09006110 T AT09006110 T AT 09006110T AT 09006110 T AT09006110 T AT 09006110T AT E503461 T1 ATE503461 T1 AT E503461T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
treating asthma
asthma
treating
pharmaceutical
Prior art date
Application number
AT09006110T
Other languages
German (de)
English (en)
Inventor
Joel A Sequeira
Stefan A Sharpe
John L Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE503461(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE503461T1 publication Critical patent/ATE503461T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT09006110T 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma ATE503461T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
ATE503461T1 true ATE503461T1 (de) 2011-04-15

Family

ID=23224164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09006110T ATE503461T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma
AT02753549T ATE430555T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02753549T ATE430555T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP1420759B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN1649568B (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE503461T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK1420759T3 (enExample)
ES (3) ES2361805T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT2092935E (enExample)
SI (2) SI1420759T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
ES2388537T3 (es) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US20050186144A1 (en) * 2004-01-21 2005-08-25 Schering Corporation Treatment methods
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
BRPI0721256A2 (pt) * 2007-02-09 2013-03-12 Schering Corp aerossàis de fÁrmaco farmacÊuticos estÁveis
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP2011509936A (ja) * 2008-01-10 2011-03-31 シェーリング コーポレイション 吸入薬物製品、システムおよび使用
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
BR112012012475B1 (pt) 2009-11-25 2020-03-03 Boehringer Ingelheim International Gmbh Nebulizador
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
ES2646201T3 (es) * 2009-12-07 2017-12-12 Horizon Orphan Llc Formulaciones de 4-metilpirazol
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
TWI597072B (zh) * 2011-10-11 2017-09-01 吉斯藥品公司 包覆脂肪酸的β－致效劑之結晶微粒
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
IL247927B (en) 2014-05-07 2022-09-01 Boehringer Ingelheim Int Container, a device that turns a liquid into a fine spray and use
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
CN116036425A (zh) 2014-05-07 2023-05-02 勃林格殷格翰国际有限公司 喷雾器、指示器装置及容器
EP3160521B1 (en) 2014-06-30 2023-06-07 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3426329A4 (en) 2016-03-09 2019-11-13 Proveris Scientific Corporation METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
WO2022081847A1 (en) 2020-10-15 2022-04-21 Proveris Scientific Corporation Systems and methods for inhaler testing

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
CA2111002C (en) * 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CZ294064B6 (cs) * 1996-08-29 2004-09-15 Schering Corporation Aerosolový suspenzní přípravek mometazonfuroátu bez chlorfluorovaných uhlovodíků
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
GB2359749B (en) * 1998-11-26 2004-05-05 Britannia Pharmaceuticals Ltd Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
ATE267582T1 (de) * 2000-01-20 2004-06-15 Basilea Pharmaceutica Ag Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
DE60239648D1 (de) 2011-05-12
CN101856362A (zh) 2010-10-13
HK1060972A1 (en) 2004-09-03
PL209640B1 (pl) 2011-09-30
NO20041277L (no) 2004-03-26
TWI324934B (en) 2010-05-21
DK2092935T3 (da) 2011-07-18
CY1111726T1 (el) 2015-10-07
US20030114428A1 (en) 2003-06-19
ES2361805T3 (es) 2011-06-22
EP1420759A2 (en) 2004-05-26
AU2002313828B2 (en) 2005-09-08
HUP0401514A2 (hu) 2004-12-28
JP2010138184A (ja) 2010-06-24
BR0212089A (pt) 2004-08-03
DE60232251D1 (de) 2009-06-18
CA2457926A1 (en) 2003-03-13
SI1420759T1 (sl) 2009-10-31
NZ530987A (en) 2006-08-31
CN1649568B (zh) 2010-10-27
ATE430555T1 (de) 2009-05-15
JP5170789B2 (ja) 2013-03-27
KR100970531B1 (ko) 2010-07-16
PL368897A1 (en) 2005-04-04
SI2092935T1 (sl) 2011-07-29
CO5560551A2 (es) 2005-09-30
AR036358A1 (es) 2004-09-01
MXPA04001875A (es) 2004-06-15
EP2092935B1 (en) 2011-03-30
HK1128428A1 (en) 2009-10-30
EP1420759B1 (en) 2009-05-06
CY1109212T1 (el) 2014-07-02
US20100143269A1 (en) 2010-06-10
HK1151987A1 (en) 2012-02-17
ZA200401419B (en) 2005-01-26
PT2092935E (pt) 2011-05-31
ES2325316T3 (es) 2009-09-01
KR20040031002A (ko) 2004-04-09
HUP0401514A3 (en) 2012-08-28
JP2005502675A (ja) 2005-01-27
US20050147565A1 (en) 2005-07-07
CN1649568A (zh) 2005-08-03
EP2319494B1 (en) 2012-06-13
JP2009185075A (ja) 2009-08-20
WO2003020253A2 (en) 2003-03-13
PT1420759E (pt) 2009-06-30
ES2389480T3 (es) 2012-10-26
EP2092935A1 (en) 2009-08-26
PE20030390A1 (es) 2003-04-24
WO2003020253A3 (en) 2003-05-22
EP2319494A1 (en) 2011-05-11
DK1420759T3 (da) 2009-08-03

Similar Documents

Publication Publication Date Title
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
FI20011478L (fi) Farmaseuttinen koostumus
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60211740D1 (de) Zusammensetzung zur saatgutbehandlung
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
IS7051A (is) Lyfjasamsetningar
FI20022128A0 (fi) Farmaseuttinen koostumus
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60121047D1 (de) Pharmazeutische zusammensetzung zur behandlung von phimose mit einem topischen corticosteroid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2092935

Country of ref document: EP